Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no furthrer therapy complete surgery
Latest Information Update: 22 Jul 2022
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2019 Results published in the European Journal of Cancer.
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.